The efficacy of CAR-T in leukemia, that is, lymphocytic leukemia, is amazing. For these patients who are refractory and relapsed, that is, those who are ineffective in conventional chemotherapy, the remission can reach 90% within one month after treatment with CAR-T, so 90% of patients can achieve complete remission after CAR-T. The overall efficiency of CAR-T for refractory multiple myeloma is 78%, which includes complete remission, partial remission and partial remission in the strict sense of the term CER, PER and SD, which means that the overall efficiency of CAR-T for refractory multiple myeloma patients who have no effect on chemotherapy is nearly 80%. The effect of CAR-T on lymphoma is a little bit worse, but it is also above 50%.